US Patent

US9526734 — Formulation of meloxicam

Formulation · Assigned to Iceutica Pty Ltd · Expires 2033-03-31 · 7y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a formulation of meloxicam in unit dosage forms containing either 5 mg or 10 mg of meloxicam.

USPTO Abstract

Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.

Drugs covered by this patent

Patent Metadata

Patent number
US9526734
Jurisdiction
US
Classification
Formulation
Expires
2033-03-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Iceutica Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.